221 related articles for article (PubMed ID: 24023300)
1. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
2. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
[TBL] [Abstract][Full Text] [Related]
3. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
[TBL] [Abstract][Full Text] [Related]
5. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
6. Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.
Balagula Y; Kang S; Patel MJ
Photodermatol Photoimmunol Photomed; 2015 Jan; 31(1):15-25. PubMed ID: 24517835
[TBL] [Abstract][Full Text] [Related]
7. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
Fortina AB; Piaserico S; Caforio AL; Abeni D; Alaibac M; Angelini A; Iliceto S; Peserico A
Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
10. GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas.
Abdou AG; Eldien MM; Elsakka D
Int J Surg Pathol; 2015 Sep; 23(6):447-53. PubMed ID: 26092229
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases.
Chaux A; Munari E; Cubilla AL; Hicks J; Lecksell K; Burnett AL; Netto GJ
Histopathology; 2014 May; 64(6):863-71. PubMed ID: 24279699
[TBL] [Abstract][Full Text] [Related]
13. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Bhat M; Watt KD
Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
16. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
18. Significance of PC cell-derived growth factor and cyclin D1 expression in cutaneous squamous cell carcinoma.
Huang K; Huang C; Shan K; Chen J; Li H
Clin Exp Dermatol; 2012 Jun; 37(4):411-7. PubMed ID: 22420613
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB
Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
